Status:
COMPLETED
Efficiency of an Algorithm Derived From Corneal Tomography Parameters to Distinguish Highly Susceptible Corneas to Ectasia From Healthy
Lead Sponsor:
Gildasio Castello de Almeida Junior
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Keratoconus, Artificial Intelligence, Support Vector Machine
Eligibility:
All Genders
Brief Summary
The objective of this study was to identify and build an algorithm through an imaging process using a support vector machine (SVM) with the tomography variables of cases with, KC, highly susceptible c...
Detailed Description
Patients were considered to be very asymmetric (VAE-NT) if the diagnosis of ectasia was confirmed in one eye based on the previously described criteria and the fellow eye had a normal front surface cu...
Eligibility Criteria
Inclusion
- Patients were considered to be very asymmetric (VAE-NT) if the diagnosis of ectasia was confirmed in one eye based on the previously described criteria and the fellow eye had a normal front surface curvature (topometric) map. Objective criteria for considering normal topography was applied for defining the cases of VAE-NT, including objective front surface curvature metrics derived from Pentacam. Normal topography was rigorously considered based on objective criteria (27, 28) of a maximum curvature Kmax (Steepest Front Keratometry) \<47.2 diopters, a paracentral inferior-superior (I-S value) asymmetry value at 6 mm (3-mm radii) \< 1.45, and keratoconus percentage index (KISA%) score \< 60 and (29). The cutoff point used to discriminate normal corneas and VAE-NT from KC corneas was the maximal posterior elevation (\< 29 µm). This cutoff point had been determined in a previous study, using the same instrument and the same setting. The posterior elevation map was displayed with a 5-mm color-coded scale, and maximal posterior elevation was measured manually using the cursor in the central 5 mm.
Exclusion
- The following exclusion criteria were adopted: history of ocular trauma; chronic use of eye medication, glaucoma; dry eye syndrome; corneal scarring; neurotrophic keratopathy; severe meibomian gland dysfunction; vulnerable state owing to physical or mental illness and with language-related difficulties; pregnant or breastfeeding.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
588 Patients enrolled
Trial Details
Trial ID
NCT04313387
Start Date
January 1 2012
End Date
January 1 2018
Last Update
March 18 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.